AdaptHealth Corp.

AdaptHealth Corp.(AHCO)财务数据

$6.390

+0.143 (+2.24%)收盘时

AHCO 收入构成

AdaptHealth Corp. (AHCO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Insurance, accounting for 61.3% of total sales, equivalent to $453.73M. Other significant revenue streams include Government and Patient Pay. Understanding this composition is critical for investors evaluating how AHCO navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

AHCO 盈利能力与利润率

Evaluating the bottom line, AdaptHealth Corp. maintains a gross margin of 13.37%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 1.60%, while the net margin is -19.47%. These profitability ratios, combined with a Return on Equity (ROE) of -16.72%, provide a clear picture of how effectively AHCO converts its operational activities into shareholder value.

AHCO 同业对比

In the context of the broader market, AHCO competes directly with industry leaders such as DNA and STLN. With a market capitalization of $826.25M, it holds a significant position in the sector. When comparing efficiency, AHCO's gross margin of 13.37% stands against DNA's 91.47% and STLN's 15.70%. Such benchmarking helps identify whether AdaptHealth Corp. is trading at a premium or discount relative to its financial performance.

AdaptHealth Corp. 财务表现

Adapthealth has faced significant financial challenges, with a reported Q2 loss of $1.07 per share and a 2.7% annual sales decline over the past two years. The gross margin has also decreased, with the latest figure at 13.37%.

Financials

FY2026Q2
YoY:
-7.50%
740.31M
Total Revenue
FY2026Q2
YoY:
-79.19%
11.87M
Operating Profit
FY2026Q2
YoY:
-1010.45%
-144.11M
Net Income after Tax
FY2026Q2
YoY:
-1080.00%
-0.98
EPS - Diluted
FY2026Q2
YoY:
-128.56%
-20.94M
Free Cash Flow
FY2026Q2
YoY:
-25.93%
13.37
Gross Profit Margin - %
FY2026Q2
YoY:
-55.68%
3.16
FCF Margin - %
FY2026Q2
YoY:
-1083.33%
-19.47
Net Margin - %
FY2025Q3
3.91
ROIC

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易